Protagonist Historical Cash Flow

PTGX Stock  USD 44.95  0.12  0.27%   
Analysis of Protagonist Therapeutics cash flow over time is an excellent tool to project Protagonist Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cashflows From Investing Activities of 110.4 M or Other Cashflows From Financing Activities of 40.3 M as it is a great indicator of Protagonist Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Protagonist Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protagonist Therapeutics is a good buy for the upcoming year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

About Protagonist Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Protagonist balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Protagonist's non-liquid assets can be easily converted into cash.

Protagonist Therapeutics Cash Flow Chart

At this time, Protagonist Therapeutics' Investments are fairly stable compared to the past year. Change In Cash is likely to rise to about 64 M in 2024, despite the fact that Sale Purchase Of Stock is likely to grow to (730.5 K).

Investments

Securities or assets acquired for generating income or appreciating in value, not used in daily operations.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Protagonist Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Protagonist Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.
Most accounts from Protagonist Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Protagonist Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagonist Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.At this time, Protagonist Therapeutics' Investments are fairly stable compared to the past year. Change In Cash is likely to rise to about 64 M in 2024, despite the fact that Sale Purchase Of Stock is likely to grow to (730.5 K).
 2023 2024 (projected)
Exchange Rate Changes19.8K17.6K
Net Borrowings16.7M15.6M

Protagonist Therapeutics cash flow statement Correlations

-0.680.49-0.15-0.08-0.02-0.230.130.24-0.040.290.23-0.050.09-0.130.40.690.190.61-0.360.430.61
-0.680.010.5-0.24-0.110.430.2-0.470.17-0.2-0.52-0.290.370.48-0.23-0.28-0.31-0.190.190.04-0.38
0.490.010.37-0.14-0.18-0.030.21-0.330.0-0.33-0.08-0.160.630.370.310.61-0.450.76-0.330.640.62
-0.150.50.37-0.81-0.470.80.81-0.80.62-0.57-0.61-0.810.920.99-0.530.41-0.74-0.230.050.690.43
-0.08-0.24-0.14-0.810.53-0.84-0.880.42-0.710.120.270.94-0.74-0.820.6-0.570.320.220.26-0.74-0.55
-0.02-0.11-0.18-0.470.53-0.35-0.310.330.150.260.320.24-0.43-0.470.56-0.520.430.110.54-0.57-0.5
-0.230.43-0.030.8-0.84-0.350.82-0.590.76-0.32-0.3-0.850.730.79-0.470.25-0.31-0.47-0.060.430.28
0.130.20.210.81-0.88-0.310.82-0.570.75-0.15-0.39-0.910.740.81-0.510.6-0.31-0.180.030.760.59
0.24-0.47-0.33-0.80.420.33-0.59-0.57-0.370.670.650.43-0.74-0.730.27-0.280.780.23-0.21-0.47-0.33
-0.040.170.00.62-0.710.150.760.75-0.37-0.15-0.02-0.880.580.62-0.280.18-0.18-0.290.140.350.26
0.29-0.2-0.33-0.570.120.26-0.32-0.150.67-0.150.360.13-0.56-0.550.190.060.830.26-0.16-0.12-0.16
0.23-0.52-0.08-0.610.270.32-0.3-0.390.65-0.020.360.26-0.36-0.590.45-0.070.590.34-0.51-0.310.05
-0.05-0.29-0.16-0.810.940.24-0.85-0.910.43-0.880.130.26-0.75-0.830.49-0.450.30.210.04-0.66-0.44
0.090.370.630.92-0.74-0.430.730.74-0.740.58-0.56-0.36-0.750.9-0.220.56-0.690.08-0.210.750.6
-0.130.480.370.99-0.82-0.470.790.81-0.730.62-0.55-0.59-0.830.9-0.560.4-0.72-0.230.040.690.42
0.4-0.230.31-0.530.60.56-0.47-0.510.27-0.280.190.450.49-0.22-0.56-0.10.350.61-0.14-0.34-0.15
0.69-0.280.610.41-0.57-0.520.250.6-0.280.180.06-0.07-0.450.560.4-0.1-0.220.45-0.50.910.94
0.19-0.31-0.45-0.740.320.43-0.31-0.310.78-0.180.830.590.3-0.69-0.720.35-0.220.15-0.15-0.45-0.32
0.61-0.190.76-0.230.220.11-0.47-0.180.23-0.290.260.340.210.08-0.230.610.450.15-0.460.320.37
-0.360.19-0.330.050.260.54-0.060.03-0.210.14-0.16-0.510.04-0.210.04-0.14-0.5-0.15-0.46-0.34-0.5
0.430.040.640.69-0.74-0.570.430.76-0.470.35-0.12-0.31-0.660.750.69-0.340.91-0.450.32-0.340.86
0.61-0.380.620.43-0.55-0.50.280.59-0.330.26-0.160.05-0.440.60.42-0.150.94-0.320.37-0.50.86
Click cells to compare fundamentals

Protagonist Therapeutics Account Relationship Matchups

Protagonist Therapeutics cash flow statement Accounts

201920202021202220232024 (projected)
Sale Purchase Of Stock36.3M216.1M(189K)(188K)(769K)(730.6K)
Investments(52.7M)(90.5M)(14.8M)92.3M26.0M27.3M
Change In Cash(49.2M)84.4M6.1M2.1M61.0M64.0M
Stock Based Compensation8.4M7.9M16.4M24.2M29.3M30.8M
Free Cash Flow(42.5M)(73.0M)(109.0M)(108.9M)(70.8M)(74.4M)
Change In Working Capital26.1M(19.0M)(3.3M)(7.8M)(19.5M)(18.5M)
Begin Period Cash Flow82.7M33.5M117.8M123.9M126.0M69.7M
Total Cashflows From Investing Activities(53.7M)(91.0M)(15.9M)91.5M105.2M110.4M
Other Cashflows From Financing Activities21.3M2.8M6.1M4.3M38.4M40.3M
Depreciation2.5M2.6M2.8M3.4M3.3M1.8M
Other Non Cash Items(557K)781K1.8M(549K)(4.4M)(4.2M)
Capital Expenditures967K471K1.1M795K609K678.9K
Total Cash From Operating Activities(41.5M)(72.5M)(107.9M)(108.1M)(70.2M)(73.7M)
Change To Account Receivables(757K)3.3M(915K)4.2M(10.0M)(9.5M)
Change To Operating Activities(2.0M)3.3M10.2M(9.8M)(8.8M)(8.3M)
Net Income(77.2M)(66.2M)(125.6M)(127.4M)(79.0M)(82.9M)
Total Cash From Financing Activities46.0M247.6M129.9M18.8M170.5M91.9M
End Period Cash Flow33.5M117.8M123.9M126.0M187.0M196.3M
Change To Netincome8.4M8.5M18.1M24.2M27.8M29.2M
Change To Liabilities(1.7M)7.7M(14.3M)(11.5M)(10.4M)(9.8M)
Change To Inventory757K(3.3M)915K(4.2M)(9.5M)(9.0M)
Cash And Cash Equivalents Changes(49.2M)84.2M6.2M2.2M2.0M1.9M
Cash Flows Other Operating31.1M(27.7M)(18.0M)4.5M4.1M4.3M
Change Receivables(2.2M)4.3M860K1.6M1.8M1.9M
Issuance Of Capital Stock34.5M255.4M123.8M14.6M132.1M107.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.